Stryker Corporation $SYK Shares Sold by Argonautica Private Wealth Management Inc.

Argonautica Private Wealth Management Inc. cut its holdings in Stryker Corporation (NYSE:SYK) by 2.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,798 shares of the medical technology company’s stock after selling 170 shares during the period. Stryker comprises about 1.0% of Argonautica Private Wealth Management Inc.’s holdings, making the stock its 29th largest position. Argonautica Private Wealth Management Inc.’s holdings in Stryker were worth $3,085,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in Stryker by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock valued at $12,306,572,000 after acquiring an additional 361,136 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after acquiring an additional 1,021,496 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after acquiring an additional 261,058 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Stryker by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock valued at $776,871,000 after acquiring an additional 83,954 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Stryker by 1.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company’s stock valued at $750,223,000 after acquiring an additional 30,329 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company’s stock.

Stryker Trading Down 0.3%

Shares of SYK stock opened at $379.96 on Wednesday. The firm has a 50-day moving average price of $379.56 and a 200 day moving average price of $379.10. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a market capitalization of $145.26 billion, a price-to-earnings ratio of 50.33, a PEG ratio of 2.75 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. During the same quarter in the prior year, the company posted $2.81 EPS. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio is currently 44.50%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SYK. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday. Truist Financial dropped their target price on shares of Stryker from $415.00 to $407.00 and set a “hold” rating for the company in a report on Wednesday, October 15th. BTIG Research raised their target price on shares of Stryker from $407.00 to $408.00 and gave the company a “buy” rating in a report on Monday, October 13th. Evercore ISI cut their target price on shares of Stryker from $418.00 to $410.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Finally, Wells Fargo & Company boosted their target price on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $431.76.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.